drugset / Trial / NCT01521962

Study of Combination Therapy With SYR-322

NCT01521962

Phase 3 Completed 67 enrolled Takeda
RandomizedParallel-group

Summary

To determine the efficacy and safety of SYR-322 (alogliptin) 25-mg, once daily (QD), in patients with diabetes when used in combination with insulin.

Timeline

Start
2012-02
Primary completion
2013-03
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Alogliptin Unknown 25 mg Oral
Comparator Insulin Protein / enzyme biologic Other

Indications